Raymond James & Associates Infla Rx N.V. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Infla Rx N.V. stock. As of the latest transaction made, Raymond James & Associates holds 267,075 shares of IFRX stock, worth $595,577. This represents 0.0% of its overall portfolio holdings.

Number of Shares

267,075

Previous 291,849 8.49%

Holding current value

$595,577

Previous $507,000 19.53%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$1.34 - $1.73 $33,197 - $42,859	-24,774 Reduced 8.49%	267,075 $408,000
Q2 2024 Jul 19, 2024	BUY	$1.18 - $1.74 $58,090 - $85,658	49,229 Added 20.29%	291,849 $507,000
Q1 2024 Apr 22, 2024	BUY	$1.47 - $2.03 $98,991 - $136,702	67,341 Added 38.42%	242,620 $373,000
Q4 2023 Jan 16, 2024	BUY	$1.25 - $2.75 $16,091 - $35,400	12,873 Added 7.93%	175,279 $285,000
Q3 2023 Oct 24, 2023	BUY	$2.66 - $4.33 $67,431 - $109,765	25,350 Added 18.5%	162,406 $483,000
Q2 2023 Jul 25, 2023	BUY	$2.05 - $6.1 $166,031 - $494,045	80,991 Added 144.46%	137,056 $611,000
Q1 2023 Apr 14, 2023	BUY	$1.66 - $3.1 $24,803 - $46,320	14,942 Added 36.33%	56,065 $108,000
Q4 2022 Feb 08, 2023	SELL	$2.11 - $3.25 $4,853 - $7,475	-2,300 Reduced 5.3%	41,123 $127,000
Q3 2022 Oct 25, 2022	BUY	$1.32 - $3.14 $5,727 - $13,624	4,339 Added 11.1%	43,423 $115,000
Q2 2022 Aug 12, 2022	BUY	$0.78 - $1.9 $1,466 - $3,572	1,880 Added 5.05%	39,084 $57,000
Q1 2022 May 11, 2022	SELL	$1.83 - $4.48 $51,858 - $126,954	-28,338 Reduced 43.24%	37,204 $68,000
Q4 2021 Feb 08, 2022	BUY	$2.35 - $5.58 $129,539 - $307,586	55,123 Added 529.06%	65,542 $312,000
Q3 2021 Nov 02, 2021	SELL	$2.25 - $3.03 $21,375 - $28,784	-9,500 Reduced 47.69%	10,419 $27,000
Q2 2021 Aug 11, 2021	SELL	$2.72 - $4.04 $58,681 - $87,158	-21,574 Reduced 51.99%	19,919 $59,000
Q1 2021 May 14, 2021	BUY	$3.62 - $6.34 $4,445 - $7,785	1,228 Added 3.05%	41,493 $162,000
Q4 2020 Feb 12, 2021	SELL	$3.82 - $5.32 $22,251 - $30,989	-5,825 Reduced 12.64%	40,265 $203,000
Q3 2020 Nov 04, 2020	BUY	$3.7 - $5.47 $170,533 - $252,112	46,090 New	46,090 $196,000

Others Institutions Holding IFRX

# of Institutions

Shares Held

12.9M

Call Options Held

19.3K

Put Options Held

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $98.6M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Infla Rx N.V. Transaction History